FDA Clears Abbott's Companion Dx for Pfizer's NSCLC Drug | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – The US Food and Drug Administration has cleared for marketing Abbott's companion diagnostic kit to detect rearrangements of the anaplastic lymphoma kinase gene in non-small cell lung cancer.

Abbott's Vysis ALK Break Apart FISH Probe is for use with Pfizer's Xalkori (crizotinib) ALK-inhibitor, whose approval was also announced by FDA on Friday after the close of the market.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic analysis of pollutant-tolerant fish, and more.

Researchers have found a rare carbapenem resistance gene on a US pig farm, NBC News reports.

New York officials are considering the use of a familial DNA search to get a lead on a suspect in the strangulation death of a runner.

NIH Director Francis Collins has selected a retired Army major general and cardiologist for the CEO spot at the agency's embattled Clinical Center.